Ultime notizie per Balchem (NASDAQ:BCPC) Azioni

Balchem

Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, agricultural, and medical sterilization industries. The segments include 1) Human Nutrition and Health segment provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. 2) The Animal Nutrition and Health segment provide nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride. 3) The Specialty Products segment includes re-packaging and distributing a number of performance gases and chemicals for various uses, notably ethylene oxide, propylene oxide, and ammonia.

Brunswick Corporation 6.375% Notes due 2049

Balchem Corp

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and raises the price target from $185 to $190.

News

Price Target

Analyst Ratings

BCPC

HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $190

WIIM

Balchem shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $1.11 by 1.8 percent. This is a 8.65 percent increase over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $239.94 million which missed the analyst consensus estimate of $241.93 million by 0.82 percent. This is a 4.35 percent increase over sales of $229.95 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Balchem Q3 Adj $1.13 Beats $1.11 Estimate, Sales $239.94M Miss $241.93M Estimate

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) will release its quarterly earnings report on Friday, 2024-10-25. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Balchem to report an earnings per share (EPS) of $1.11.
The market awaits Balchem's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.06 in the last quarter, leading to a 0.0% drop in the share price on the following day.
Here's a look at Balchem's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.03</td>
<td>0.99</td>
<td>0.93</td>
<td>0.97</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.09</td>
<td>1.03</td>
<td>0.95</td>
<td>1.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>3.0%</td>
<td>2.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729782112_0.png" alt="eps graph" />
<h3>Performance of Balchem Shares</h3>
Shares of Balchem were trading at $166.76 as of October 23. Over the last 52-week period, shares are up 44.86%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BCPC/earnings">To track all earnings releases for Balchem visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Balchem

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and raises the price target from $170 to $185.

HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $185

When it comes to short-term investing or trading, they say &quot;the trend is your friend.&quot; And there&#39;s no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.
The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.
Our &quot;Recent Price Strength&quot; screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent uptrend. Also, the screen passes only the stocks that are trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
Blachem (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcpc#NASDAQ">BCPC</a>) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for &quot;trend&quot; investors.
A solid price increase over a period of 12 weeks reflects investors&#39; continued willingness to pay more for the potential upside in a stock. BCPC is quite a good fit in this regard, gaining 20.2% over this period.
However, it&#39;s not enough to look at the price change for around three months, as it doesn&#39;t reflect any trend reversal that might have happened in a shorter time frame. It&#39;s important for a potential winner to maintain the price trend. A price increase of 17.4% over the past four weeks ensures that the trend is still in place for the stock of this chemical company.
Moreover, BCPC is currently trading at 97.5% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock&#39;s near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
Another factor that confirms the company&#39;s fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock&#39;s near-term price performance.
So, the price trend in BCPC may not reverse anytime soon.
<a href="https://www.zacks.com/stock/news/2310616/blachem-bcpc-is-on-the-move-here-s-why-the-trend-could-be-sustainable?cid=CS-BENZ-FT-tale_of_the_tape|recent_price_strength_screen-2310616">To read this article on Zacks.com click here.</a>

Markets

Trading Ideas

Blachem is on the Move, Here's Why the Trend Could be Sustainable

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $1.03 by 5.83 percent. This is a 2.83 percent increase over earnings of $1.06 per share from the same period last year. The company reported quarterly sales of $234.08 million which missed the analyst consensus estimate of $239.69 million by 2.34 percent. This is a 1.22 percent increase over sales of $231.25 million the same period last year.

Balchem Q2 Adj $1.09 Beats $1.03 Estimate, Sales $234.08M Miss $239.69M Estimate

Avian influenza, also known as bird flu, has public health <a href="https://www.benzinga.com/news/24/07/39594907/amid-rapidly-rising-bird-flu-cases-moderna-lands-176m-worth-us-government-contract-for-vaccine">officials on alert</a> after it spread to an unprecedented number of cows in the U.S. this year and led to positive tests of the virus in four U.S. dairy workers so far this year.
A severe variant of the H5N1 strain infected animals ranging from alpacas to house cats worldwide since 2020 and caused lethal outbreaks in commercial poultry, but this is the first year it has infected cows, Reuters reported.
Humans have contracted different bird flu strains in Australia and Mexico, while different H5 subtypes have also shown up in other parts of the world including China and Cambodia.
Most of the human cases have come from exposure to poultry, live poultry markets and dairy cattle, but scientists worry the virus could mutate so it could easily spread between humans and spark a pandemic. The World Health Organization says the risk to people is low at this point, Reuters reported.
The first known bird flu cases happened in Texas in March, and now the virus has infected dairy herds in 12 states. The U.S. Agriculture Department said tests so far reveal that the virus detected in cows is the same H5N1 virus affecting wild birds and commercial poultry flocks.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/06/39213667/first-human-death-from-bird-flu-strain-puts-vaccine-stocks-back-on-the-map">First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map</a>
The four dairy workers who have tested positive for the virus this year had mild symptoms such as conjunctivitis, or pink eye.
Michigan, which has two of the four cases infecting dairy workers, has led the nation in efforts to stop the spread of bird flu and prevent negative impacts to the state&#8217;s dairy industry. 
State restrictions include tracking who comes and goes from farms as Michigan tests more people than any of the 12 states with confirmed cases in cows, according to a Reuters survey of state health departments. 
So far this year, various forms of bird flu have been detected in 21 people worldwide, according to Reuters.
Price Action: Most companies busy developing bird-flu vaccines saw gains on Wednesday. Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) picked up 1.18% to close at $117.44, while GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) slipped 0.12% to $38.56 and Carlisle Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) gained 2.28% to $416.88.
Dairy stocks and agriculture and dairy cattle exchange-traded funds gave mixed reactions. AGCO Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) gained 0.69% to close at $94.21 on Wednesday as Aemetis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMTX#NASDAQ">AMTX</a>) declined 3.18% to $3.35 and Balchem Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) picked up 0.60% to $162.89.
Invesco DB Agriculture Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBA#NYSE">DBA</a>) declined 1.23% on Wednesday to $1.23, while First Trust Dow Jones Select MicroCap Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDM#NYSE">FDM</a>) rose 1.71% to $59.51 and Invesco S&amp;P SmallCap 600 Pure Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RZV#NYSE">RZV</a>) improved 1.32% to $98.
<h4 class="wp-block-heading">Read Now:</h4>
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39710325/investor-that-backed-moderna-raises-3-6b-for-ai-driven-biotech-ventures">Investor That Backed Moderna Raises $3.6B For AI-driven Biotech Ventures</a></li>
</ul>
Photo: Shutterstock

Health Care

ETFs

AGCO

AMTX

First Trust/First Trust Dow Jones Select MicroCap Index Fund

MRNA

Rydex ETF Trust S&P Smallcap 600 Pure Value ETF

Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time

As of July 9, 2024, two stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Balchem Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>)</h3>
<ul>
<li>On May 3, Balchem posted better-than-expected first-quarter results. Ted Harris, Chairman, President and CEO of Balchem said, &#8220;The first quarter was a very good start to the year for Balchem. We delivered record net sales, adjusted EBITDA, and net earnings, as well as solid first quarter cash flows, despite the continued challenging environment in parts of our portfolio.&#8221; The company's stock gained around 6% over the past five days and has a <a href="https://www.benzinga.com/quote/BCPC">52-week high of $163.02</a>.</li>
<li>RSI Value: 70.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>BCPC Price Action: Shares of Balchem gained 1.1% to close at $162.28 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Anglogold Ashanti PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>)</h3>
<ul>
<li>On July 3, JP Morgan analyst Patrick Jones maintained Anglogold Ashanti with an Overweight and lowered the price target from $33 to $32. The company's stock gained around 25% over the past month and <a href="https://www.benzinga.com/quote/AU">has a 52-week high</a> of $29.08.</li>
<li>RSI Value: 71.29</li>
<li>AU Price Action: Shares of Anglogold Ashanti fell 1.9% to close at $28.27 on Monday.</li>
</ul>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39665755/wall-streets-most-accurate-analysts-say-buy-these-3-utilities-stocks-delivering-high-div">Wall Street&#8217;s Most Accurate Analysts Say Buy These 3 Utilities Stocks Delivering High-Dividend Yields</a>

Short Ideas

Pre-Market Outlook

Top 2 Materials Stocks You May Want To Dump This Month

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Wedbush raised the price target for BJ&#8217;s Restaurants, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) from $40 to $43. Wedbush analyst Nick Setyan maintained an Outperform rating. BJ&#8217;s Restaurants shares rose 5.9% to close at $34.68 on Friday. <a href="https://www.benzinga.com/quote/BJRI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted the price target for Robinhood Markets, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from $20 to $21. Mizuho analyst Dan Dolev maintained a Buy rating. Robinhood shares rose 1.9% to close at $17.95 on Friday. <a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut Fox Factory Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXF#NASDAQ">FOXF</a>) price target from $55 to $48. B of A Securities analyst Alexander Perr maintained a Neutral rating. Fox Factory shares rose 10.4% to close at $43.52 on Friday. <a href="https://www.benzinga.com/quote/FOXF/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased the price target for Franco-Nevada Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) from $175 to $185. HC Wainwright &amp; Co. analyst Heiko Ihle maintained a Buy rating. Franco-Nevada shares rose 1.9% to close at $123.25 on Friday. <a href="https://www.benzinga.com/quote/FNV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) price target from $42 to $46. Baird analyst Andrew Wittmann maintained an Outperform rating. Fluor shares fell 5.7% to close at $38.90 on Friday. <a href="https://www.benzinga.com/quote/FLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler increased Essex Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) price target from $291 to $315. Piper Sandler analyst Alexander Goldfarb maintained an Overweight rating. Essex Property Trust shares gained 0.2% to close at $250.31 on Friday. <a href="https://www.benzinga.com/quote/ESS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised the price target for Balchem Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) from $167 to $170. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Balchem shares rose 2.8% to close at $150.40 on Friday. <a href="https://www.benzinga.com/quote/BCPC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein boosted American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) price target from $21 to $22. Bernstein analyst David Vernon maintained an Outperform rating. American Airlines shares fell 0.1% to close at $13.85 on Friday. <a href="https://www.benzinga.com/quote/AAL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley increased Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) price target from $16 to $18. Morgan Stanley analyst Patrick Wood upgraded the stock from Equal-Weight to Overweight. Bausch + Lomb shares fell 1.9% to close at $13.60 on Friday. <a href="https://www.benzinga.com/quote/BLCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush increased Mid-America Apartment Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>) price target from $135 to $154. Wedbush analyst Richard Anderson upgraded the stock from Neutral to Outperform. Mid-America Apartment shares rose 1% to close at $133.00 on Friday. <a href="https://www.benzinga.com/quote/MAA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/05/38614014/coinbase-global-doordash-and-2-other-stocks-insiders-are-selling">Coinbase Global, DoorDash And 2 Other Stocks Insiders Are Selling</a>

BJRI

BLCO

FOXF

HOOD

American Airlines To Rally Around 59%? Here Are 10 Top Analyst Forecasts For Monday

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and raises the price target from $167 to $170.

HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $170

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.99 by 4.04 percent. This is a 9.57 percent increase over earnings of $0.94 per share from the same period last year. The company reported quarterly sales of $239.66 million which beat the analyst consensus estimate of $232.46 million by 3.10 percent. This is a 3.06 percent increase over sales of $232.54 million the same period last year.

Balchem Q1 Adj $1.03 Beats $0.98 Estimate, Sales $239.66M Beat $232.46M Estimate

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) reported quarterly earnings of $0.95 per share which beat the analyst consensus estimate of $0.93 by 2.15 percent. This is a 1.06 percent increase over earnings of $0.94 per share from the same period last year. The company reported quarterly sales of $228.70 million which missed the analyst consensus estimate of $234.66 million by 2.54 percent. This is a 1.65 percent decrease over sales of $232.53 million the same period last year.

Balchem Q4 Adj. EPS $0.95 Beats $0.93 Estimate, Sales $228.70M Miss $234.66M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $97.65 million.
&bull; Liberty Broadband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDK#NASDAQ">LBRDK</a>) is projected to report quarterly earnings at $2.33 per share on revenue of $248.00 million.
&bull; Telephone and Data (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $1.28 billion.
&bull; TC Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRP#NYSE">TRP</a>) is likely to report quarterly earnings at $1.09 per share on revenue of $4.21 billion.
&bull; United States Cellular (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $984.23 million.
&bull; Cinemark Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) is expected to report quarterly loss at $0.14 per share on revenue of $613.23 million.
&bull; Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) is expected to report quarterly earnings at $0.88 per share on revenue of $747.58 million.
&bull; Barnes Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>) is expected to report quarterly earnings at $0.35 per share on revenue of $420.47 million.
&bull; DT Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>) is estimated to report quarterly earnings at $0.92 per share on revenue of $234.45 million.
&bull; American Axle &amp; Mfg Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>) is projected to report quarterly loss at $0.19 per share on revenue of $1.42 billion.
&bull; Treehouse Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THS#NYSE">THS</a>) is expected to report quarterly earnings at $0.73 per share on revenue of $925.44 million.
&bull; AdvanSix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASIX#NYSE">ASIX</a>) is estimated to report quarterly loss at $0.21 per share on revenue of $335.87 million.
&bull; Marcus &amp; Millichap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMI#NYSE">MMI</a>) is likely to report quarterly loss at $0.28 per share on revenue of $171.20 million.
&bull; Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) is projected to report quarterly earnings at $0.93 per share on revenue of $234.66 million.
&bull; PPL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $1.90 billion.
&bull; Associated Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AC#NYSE">AC</a>) is expected to report quarterly loss at $0.03 per share on revenue of $5.11 billion.
&bull; Liberty Broadband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) is expected to report quarterly earnings at $3.44 per share on revenue of $250.00 million.
&bull; Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) is expected to report quarterly earnings at $1.39 per share on revenue of $1.83 billion.
&bull; Healthcare Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) is likely to report earnings for its fourth quarter.
&bull; Eni (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/E#NYSE">E</a>) is projected to report earnings for its fourth quarter.
&bull; NatWest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWG#NYSE">NWG</a>) is expected to report earnings for its fourth quarter.
<h3>&nbsp;</h3>
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ASIX

LBRDA

LBRDK

Earnings Scheduled For February 16, 2024

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) is set to give its latest quarterly earnings report on Friday, 2024-02-16. Here's what investors need to know before the announcement.
Analysts estimate that Balchem will report an earnings per share (EPS) of $0.93. 
Balchem bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.07, which was followed by a 0.0% drop in the share price the next day.
Here's a look at Balchem's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.97</td>
<td>0.84</td>
<td>0.70</td>
<td>0.83</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.04</td>
<td>1.06</td>
<td>0.94</td>
<td>0.94</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.42%</td>
<td>1.8%</td>
<td>4.05%</td>
<td>-0.87%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1708009221_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Balchem were trading at $142.73 as of February 14. Over the last 52-week period, shares are up 2.51%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BCPC/earnings">To track all earnings releases for Balchem visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Balchem Earnings Preview

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays increased AbbVie Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abbv#NYSE">ABBV</a>) price target from $160 to $170. Barclays analyst Carter Gould upgraded the stock from Equal-Weight to Overweight. AbbVie shares fell 4.3% to close at $138.93 on Friday. <a href="https://www.benzinga.com/quote/ABBV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for Olin Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oln#NYSE">OLN</a>) from $75 to $48. JP Morgan analyst Jeffrey Zekauskas downgraded the stock from Overweight to Neutral. Olin shares fell 9% to close at $42.12 on Friday. <a href="https://www.benzinga.com/quote/OLN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS increased East West Bancorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ewbc#NASDAQ">EWBC</a>) price target from $57 to $61. UBS analyst Brody Preston upgraded the stock from Neutral to Buy. East West Bancorp shares gained 1.6% to $53.50 in pre-market trading. <a href="https://www.benzinga.com/quote/EWBC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James slashed the price target for Chevron Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvx#NYSE">CVX</a>) from $200 to $175. Raymond James analyst Justin Jenkins maintained an Outperform rating. Chevron shares gained 1.8% to $146.87 in pre-market trading. <a href="https://www.benzinga.com/quote/CVX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc cut the price target for Eastman Chemical Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/emn#NYSE">EMN</a>) from $98 to $95. Keybanc analyst Aleksey Yefremov maintained an Overweight rating. Eastman Chemical shares rose 3.5% to close at $72.58 on Friday. <a href="https://www.benzinga.com/quote/EMN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut NorthWestern Energy Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nwe#NYSE">NWE</a>) price target from $59 to $51. Wells Fargo analyst Jonathan Reeder upgraded the stock from Equal-Weight to Overweight. NorthWestern Energy shares fell 2.3% to close at $46.55 on Friday. <a href="https://www.benzinga.com/quote/NWE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird slashed Datadog, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddog#NASDAQ">DDOG</a>) price target from $100 to $84. Baird analyst William Power downgraded the stock from Outperform to Neutral. Datadog shares fell 0.7% to $81.13 in pre-market trading. <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut the price target for Balchem Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcpc#NASDAQ">BCPC</a>) from $165 to $135. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Balchem shares fell 5.4% to close at $115.08 on Friday. <a href="https://www.benzinga.com/quote/BCPC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut CubeSmart (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cube#NYSE">CUBE</a>) price target from $51 to $38. B of A Securities analyst Jeffrey Spector downgraded the stock from Buy to Neutral. CubeSmart shares fell 0.7% to close at $33.98 on Friday. <a href="https://www.benzinga.com/quote/CUBE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James cut Axos Financial, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ax#NYSE">AX</a>) price target from $55 to $45. Raymond James analyst David Feaster maintained an Outperform rating. Axos Financial shares fell 7.8% to close at $34.85 on Friday. <a href="https://www.benzinga.com/quote/AX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/10/35483899/fear-among-us-investors-is-growing-fear-greed-index-moves-to-extreme-fear-zone"> Fear Among US Investors Is Growing; Fear &amp; Greed Index Moves To &#39;Extreme Fear&#39; Zone </a>

ABBV

CUBE

DDOG

EWBC

AbbVie To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Monday

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and lowers the price target from $165 to $135.

HC Wainwright & Co. Maintains Buy on Balchem, Lowers Price Target to $135

Balchem shares are trading lower after the company reported mixed Q3 financial results.

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.97 by 7.22 percent. This is a 4 percent increase over earnings of $1.00 per share from the same period last year. The company reported quarterly sales of $229.95 million which missed the analyst consensus estimate of $237.08 million by 3.01 percent. This is a 5.86 percent decrease over sales of $244.27 million the same period last year.

Balchem Q3 Adjusted EPS $1.04 Beats $0.97 Estimate, Sales $229.95M Miss $237.08M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) is projected to report quarterly earnings at $2.26 per share on revenue of $12.56 billion.
&bull; Equinor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) is estimated to report earnings for its third quarter.
&bull; Standard Motor Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMP#NYSE">SMP</a>) is estimated to report quarterly earnings at $0.98 per share on revenue of $391.23 million.
&bull; Piper Sandler (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PIPR#NYSE">PIPR</a>) is expected to report quarterly earnings at $1.58 per share on revenue of $298.82 million.
&bull; Civista Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIVB#NASDAQ">CIVB</a>) is estimated to report quarterly earnings at $0.61 per share on revenue of $40.88 million.
&bull; Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) is likely to report quarterly earnings at $0.13 per share on revenue of $2.69 billion.
&bull; T. Rowe Price Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) is expected to report quarterly earnings at $1.78 per share on revenue of $1.62 billion.
&bull; AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is estimated to report quarterly earnings at $2.70 per share on revenue of $12.92 billion.
&bull; First Hawaiian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHB#NASDAQ">FHB</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $199.90 million.
&bull; Fomento Economico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMX#NYSE">FMX</a>) is estimated to report quarterly earnings at $1.40 per share on revenue of $11.67 billion.
&bull; Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $566.22 million.
&bull; Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) is expected to report quarterly earnings at $1.91 per share on revenue of $13.29 billion.
&bull; WisdomTree (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WT#NYSE">WT</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $88.63 million.
&bull; Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) is estimated to report quarterly earnings at $3.62 per share on revenue of $745.98 million.
&bull; AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) is estimated to report quarterly earnings at $2.73 per share on revenue of $1.89 billion.
&bull; Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $99.96 million.
&bull; LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) is estimated to report quarterly earnings at $2.02 per share on revenue of $10.10 billion.
&bull; Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) is projected to report quarterly earnings at $2.24 per share on revenue of $83.76 billion.
&bull; Barnes Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>) is projected to report quarterly earnings at $0.48 per share on revenue of $356.50 million.
&bull; Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) is likely to report quarterly earnings at $3.33 per share on revenue of $47.79 billion.
&bull; Fortis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTS#NYSE">FTS</a>) is likely to report quarterly earnings at $0.81 per share on revenue of $2.91 billion.
&bull; Carter&#39;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) is likely to report quarterly earnings at $1.54 per share on revenue of $786.35 million.
&bull; Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) is likely to report quarterly earnings at $1.27 per share on revenue of $4.00 billion.
&bull; Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) is projected to report quarterly earnings at $4.76 per share on revenue of $38.96 billion.
&bull; Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) is expected to report quarterly earnings at $7.94 per share on revenue of $13.63 billion.
&bull; CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) is likely to report quarterly earnings at $0.67 per share on revenue of $7.42 billion.
&bull; ArcBest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) is likely to report quarterly earnings at $1.50 per share on revenue of $1.13 billion.
&bull; Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) is likely to report quarterly earnings at $0.83 per share on revenue of $3.97 billion.
&bull; Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) is expected to report quarterly earnings at $0.54 per share on revenue of $749.17 million.
&bull; NatWest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWG#NYSE">NWG</a>) is likely to report earnings for its third quarter.
&bull; Lincoln Electric Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LECO#NASDAQ">LECO</a>) is projected to report quarterly earnings at $2.25 per share on revenue of $1.04 billion.
&bull; Stellar Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEL#NYSE">STEL</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $109.35 million.
&bull; AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) is projected to report quarterly earnings at $5.49 per share on revenue of $6.72 billion.
&bull; Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) is expected to report quarterly earnings at $0.80 per share on revenue of $4.82 billion.
&bull; nVent Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) is likely to report quarterly earnings at $0.73 per share on revenue of $881.14 million.
&bull; Cumulus Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMLS#NASDAQ">CMLS</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $207.47 million.
&bull; Oil States International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $189.85 million.
&bull; Gorman-Rupp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRC#NYSE">GRC</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $163.79 million.
&bull; Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) is likely to report quarterly earnings at $0.97 per share on revenue of $237.08 million.
&bull; Alliance Res Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARLP#NASDAQ">ARLP</a>) is likely to report quarterly earnings at $1.28 per share on revenue of $667.56 million.
&bull; Virtus Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NASDAQ">VRTS</a>) is likely to report quarterly earnings at $6.21 per share on revenue of $200.57 million.
&bull; Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) is estimated to report quarterly earnings at $0.21 per share on revenue of $166.74 million.
&bull; Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) is expected to report quarterly earnings at $0.23 per share on revenue of $2.12 billion.
&bull; Eni (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/E#NYSE">E</a>) is likely to report earnings for its third quarter.
&bull; Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) is projected to report quarterly earnings at $1.33 per share on revenue of $2.61 billion.
&bull; Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) is estimated to report quarterly earnings at $2.21 per share on revenue of $2.89 billion.
&bull; PNM Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNM#NYSE">PNM</a>) is likely to report quarterly earnings at $1.34 per share on revenue of $651.91 million.
&bull; Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) is estimated to report quarterly earnings at $1.61 per share on revenue of $1.04 billion.
&bull; Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $1.71 billion.
<h3>Companies Reporting After The Bell</h3>
&bull; Socket Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCKT#NASDAQ">SCKT</a>) is projected to report quarterly loss at $0.07 per share on revenue of $5.22 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ARCB

ARLP

AVTR

CBRE

CHTR

CIVB

CMLS

CVEO

EQNR

Fomento Economico Mexicano S.A.B. De C.V.

GNTX

GTLS

LECO

PIPR

SAIA

SCKT

STEL

TROW

VRTS

Earnings Scheduled For October 27, 2023

Balchem Non-GAAP EPS of $1.09 beats by $0.06, revenue of $234.08M misses by $5.61M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Balchem (NASDAQ:<a href="https://investorplace.com/stock-quotes/bcpc-stock-quote/">BCPC</a>) just reported results for the second quarter of 2024.<ul><li>Balchem reported earnings per share of $1.09. This was above the analyst estimate for EPS of $1.03.</li><li>The company reported revenue of $234.08 million.</li><li>This was 2.34% worse than the analyst estimate for revenue of $239.69 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/07/bcpc-stock-earnings-balchem-for-q2-of-2024/">BCPC Stock Earnings: Balchem Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BCPC Stock Earnings: Balchem Beats EPS, Misses Revenue for Q2 2024

Balchem Corporation 2024 Q2 - Results - Earnings Call Presentation

Balchem Corporation (BCPC) Q2 2024 Earnings Call Transcript

An update from Balchem ( ($BCPC) ) is now available. Balchem Corporation has adjusted the composition of its Board of Directors to ensure an equal ...

Balchem Board Restructures for Balanced Governance

Balchem Q3 2024 Earnings Preview

Balchem Non-GAAP EPS of $1.13 beats by $0.02, revenue of $239.94M misses by $1.99M

Balchem Corporation (BCPC) Q3 2024 Earnings Call Transcript

Balchem's Q3 Shows Record Earnings And Valuation Pressure

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Balchem (BCPC – Research Report). The associated price target is $190....

Comments

Balchem

Notizie

Ultime notizie per Balchem (NASDAQ:BCPC) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO